Cytodyn Inc (CYDY)

[finesand]

re Pro 140 Review (WIP), our opinion/findings

Science is genuine, Pro 140 found before 1999 and is well covered in the scientific community via peer reviewed papers - undisputed.

Safety profile is extraordinary, especially since Pro 140 does not impact CCR5 host receptor normal cause of operations.

2017's CROI poster's data also demonstrated how well Pro 140 does scale with dosage and frequency of administration. The Viral Load suppression curve matches its method of action.

Efficacy on CCR5-tropic HIV-1 has been proven since 2010 and we are looking forward to the latest trial data, a paper before June's ASM and/or the poster at June's ASM the latest.

+++

And now, we can simply wait until market catches up with the science and commercial application.